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doi:10.1016/j.ejvs.2011.06.029Abstract Objectives: The objective was to evaluate the impact of gender on long-term
survival of patients who underwent non-cardiac vascular surgery.
Design, Material and Methods: Our prospectively collected data contained information on 560
patients undergoing carotid endarterectomy (CEA), 923 elective abdominal aortic aneurysm
repairs (AAA) and 1046 lower limb reconstructions (LLR). Patient characteristics and long-
term mortality of women were compared to that of men. KaplaneMeier (KM) survival curves
were constructed for men and women, on which we superimposed age- and sex-matched KM
survival curves of the general population. Cox proportional hazards regression was used to
identify risk factors for mortality.
Results: Men in the CEA group had statistically significant higher all-cause mortality, hazard
rate ratio (HRR) 1.41 (95% CI 1.01e1.98) No differences in mortality between the genders were
observed in the AAA and LLR groups.
Overall, men had more co-morbidities but received more disease-specific medication
compared to women. Women retained their higher life expectancy after CEA but lost it in
the AAA and LLR groups.
Conclusion: Women retain their higher life expectancy after CEA; however, after AAA repair
and LLR, this advantage is lost. Both men and women received too little disease-specific medi-
cation, but women were worse off.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.0 7043489; fax: þ31 10 7044657.
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Cardiovascular disease has long been neglected as the
leading cause of death in women. The reason for this is
twofold. On the one hand, women themselves worry more
about easily identifiable (female) diseases such as breast
cancer. On the other hand, doctors are less inclined to think
of cardiovascular disease in women, and the clinical
presentation in women can be different from that in men,
leading to delay in diagnosis or even the diagnosis being
missed.1 For coronary artery disease in particular, gender
disparities are well documented. Women are diagnosed
later compared to men, and are then treated less aggres-
sively.2,3 Women receive fewer coronary angiography and
revascularisation procedures and have higher complication
and mortality rates following revascularisation.4e6 The
difference is resolved when looking at long-term survival.7
Reports are fewer for non-cardiac vascular disease, but
the mechanisms are thought to be similar. Just as with
coronary heart disease, women with carotid artery disease
have worse short-term outcome after carotid revascular-
isation.8,9 Women with abdominal aortic aneurysms are also
diagnosed later (at a later stage of disease), have lower
probability of being admitted to hospital and receiving
treatment and have worse short-term outcome.10e12 For
peripheral arterial occlusive disease (PAOD), lower patency
rates and worse survival for women have been repor-
ted.13,14 Gender-specific data for long-term outcomes for
non-cardiac vascular disease are sparse. All major trials/
RCTs on carotid artery disease, abdominal aortic aneurysm
and peripheral artery occlusive disease focused on differ-
ences in outcome between treatment types (open surgery
vs. endovascular treatment) and not on gender.
Given the higher life expectancy of women at all ages,
but their supposedly worse short-term outcome, it would
be interesting to see whether women retain their higher
life expectancy once they are operated for non-cardiac
vascular disease.
Our objective was to evaluate the impact of gender on
prognosis of patients who underwent non-cardiac vascular
procedures, namely carotid artery revascularisation, intact
abdominal aortic aneurysm repair or lower extremity
revascularisation. We evaluated whether differences in
pre-operative risk factors between men and women were
present and how these differences influenced long-term
survival.
Materials and Methods
From January 1993 until November 2006, data on all
patients undergoing non-cardiac open vascular surgery at
the Erasmus MC, Rotterdam, the Netherlands, were
prospectively entered in a computerised database. All
patients underwent open surgery for one of the following
diseases: 1) symptomatic carotid artery stenosis, 2) intact
infrarenal abdominal aortic aneurysm, 3) peripheral arte-
rial occlusive disease.
Patients with carotid artery stenosis underwent an
elective reconstruction or desobstruction of the carotid
artery (CEA). Patients in the AAA group underwent open
infrarenal AAA repair. Patients with PAOD underwent lowerleg revascularisation (LLR) of the iliac-femoral, femoral-
popliteal, or femoral-tibial artery.
For all patients, age, gender, cardiovascular risk factors,
disease history and medication use at the time of operation
were recorded. Cardiovascular risk factors included
smoking status, hypertension (defined as systolic blood
pressure 140 mmHg, diastolic blood pressure 90 mmHg,
and/or use of antihypertensive medication), diabetes
mellitus (the presence of a fasting blood glucose
140 mg dl1 or requirement for insulin or oral hypogly-
cemic agents), hypercholesterolemia (total cholesterol of
>200 mg dl1 and/or the requirement of lipid-lowering
medication), chronic obstructive pulmonary disease
(COPD) according to symptoms or pulmonary function tests
(i.e., forced expiratory volume in 1 s <70% of maximal age
and gender predictive value) and renal dysfunction (base-
line creatinine >1.5 mg dle1).
Disease history included the presence of ischaemic heart
disease (prior MI, prior coronary revascularisation (coronary
artery bypass graft or percutaneous coronary intervention)
and angina pectoris) and heart failure (defined according to
the New York Heart Association’s functional classification).
Medication recorded included statins, diuretics, ACE
inhibitors, calcium antagonist, nitrates, beta-blockers,
aspirin and anticoagulants.
Follow-up information was retrieved from our hospitals’
electronic database. Missing outcome data were retrieved
by reviewing patients’ medical charts. Survival status was
furthermore obtained from the municipal civil registries.
Mean follow-up was 6.40  4.12 years. Follow-up was
complete for 92% of cases: 519/560 (93%) in the CEA group
(91% for women and 93% for men), 906/923 (98%) for the
AAA group (98% for both women and men) and in 898/1046
(86%) for the LLR group (83% for women and 87% for men).
Multivariable analysis was based on complete cases. We had
no missing data of predictors.
Outcomes
Mortality was subdivided into cardio-cerebrovascular death
(CCVD), non-CCVD and death due to unknown cause(s).
CCVD consisted of cardiac (MI, congestive heart failure and
arrhythmia) stroke, fatal bleeding and other deaths. Non-
CCVD consisted of infection, malignancy, respiratory
insufficiency and other deaths.
All-cause mortality was the combination of CCVD, non-
CCVD and death due to unknown cause(s).
Statistical methods
For each of the three disease groups, the data were pre-
sented for women and men separately. Continuous vari-
ables were expressed as mean  SD, and categorical
variables were presented as frequencies. Differences in
patient characteristics (age, gender, cardiovascular risk
factors, disease history and medication use) were
compared with t-tests, Wilcoxon tests or the X2 statistic, as
appropriate. Differences in mortality between women and
men were tested using the c2 statistic. KaplaneMeier (KM)
survival analysis was used to compare survival times
between women and men, stratified by disease group. To
512 N. Grootenboer et al.test for differences, the log-rank test was used. KM survival
curves for the general population (age- and sex-matched to
the study population) were superimposed on the disease-
specific KM curves. Long-term survival was analysed for
women and men by means of Cox proportional hazards
regression models. Risk factors entered into the models
were: age, gender, hypertension, diabetes, hypercholes-
terolemia, COPD, renal dysfunction, current smoking,
angina, heart failure, MI, previous coronary revascularisa-
tion (PCI/CABG), statin use, b-blocker use and aspirin use.
We included those that died within 30 days of surgery in the
long-term (survival) analysis. The hazard rate ratio (HRR)
for mortality of women vs. men was calculated.
All tests were performed two-sided, and a probability
value of <0.05 was considered statistically significant. All
analyses were performed with SPSS software version 17.
The authors had full access to the data and take full
responsibility for their integrity. All authors have read and
agreed to the manuscript as written.
Results
Carotid disease
In Table 1, the patient characteristics of the 560 patients
who underwent CEA surgery are depicted. In short, no
difference in age was found between men and women (65Table 1 Patient characteristics.
CEA AAA
Female Male p-value Fema
n (%) 154 (27.5) 406 (72.5) 199 (
Mean age (SD) 64.93
(10.58)
64.99
(9.44)
0.943 63.0
(1
Cardiovascular risk factor
Hypertension 53 (34) 139 (34.2) 0.968 108 (
Diabetes Mellitus 15 (9.7) 41 (10.1) 0.9 29 (
Hypercholesterolemia 17 (11.0) 49 (12.1) 0.736 47 (
COPD 9 (5.8) 28 (6.9) 0.654 41 (
Renal dysfunction 3 (1.9) 23 (5.7) 0.062 18 (
Current smoker 6 (3.9) 55 (13.5) 0.001 64 (
Disease history
Angina 7 (4.5) 30 (7.4) 0.226 31 (
Heart failure 1 (0.6) 5 (1.2) 0.55 12 (
MI 4 (2.6) 45 (11.1) 0.002 47 (
Intervention 19 (12) 85 (20.9) 0.019 43 (
PCI 12 (7.8) 36 (8.9) 0.685 16 (
CABG 9 (5.8) 67 (16.5) 0.01 34 (
Medication use
Statins 44 (28.6) 100 (24.6) 0.341 68 (
Beta-blockers 37 (24.0) 108 (26.6) 0.535 83 (
ACE inhibitors 27 (17.5) 92 (22.7) 0.185 76 (
Calcium antagonists 42 (27.3) 108 (26.7) 0.837 74 (
Aspirin 103 (66.9) 308 (75.9) 0.032 49 (
Nitrates 16 (10.4) 57 (14.0) 0.252 40 (
Diuretics 19 (12.3) 34 (8.4) 0.153 44 (
Anticoagulation 9 (5.8) 26 (6.4) 0.807 26 (
For statistical significance of data in bold please refer to Statistical Myears vs. 65 years; pZ 0.94) but compared to women, men
more often were current smokers, had a previous history of
an MI intervention, CABG, and more often used aspirin.
There were 224 deaths (48 women and 176 men) and
higher mortality was seen for men, compared to women,
for cardiac, CCVD and overall death (Table 2). The KM
survival curves (Fig. 1a) depict the all-cause mortality for
women and men separately and the log-rank test
(p Z 0.007) demonstrates worse survival for men. The
disease-specific KM survival curves are lower than the age-
and sex-matched curves of the general population. Women
do retain their higher life expectancy compared to men
after carotid endarterectomy. The unadjusted HRR for men
in predicting all-cause mortality was 1.54 (95% CI
1.12e2.12) (not shown). After adjustment (Table 3), men
still had significantly worse all-cause mortality (HRR 1.41;
95% CI 1.01e1.98). Other variables independently associ-
ated with worse all-cause mortality were age, diabetes,
hypercholesterolemia, renal dysfunction and previous MI. A
history of angina was associated with better survival.
The unadjusted HRR for cardiac mortality was 2.55 (95%
CI 1.25e5.19) (not shown). After adjustment (Table 3), men
no longer had statistically significant worse cardiac
mortality HRR 2.02 (95% CI 0.95e4.32). Variables indepen-
dently associated with worse cardiac mortality were age,
hypercholesterolemia, previous MI, previous intervention
and use of beta-blockers. A history of angina was associated
with better survival.LLR
le Male p-value Female Male p-value
21.6) 724 (78.4) 293 (28) 753 (72)
4
3.4)
67.33
(10.16)
0.000 66.47
(12.99)
64.99
(11.37)
0.070
54.3) 384 (53.0) 0.758 153 (52.2) 329 (43.7) 0.013
14.6) 87 (12.0) 0.335 66 (22.5) 147 (19.5 0.283
23.6) 159 (22.0) 0.619 55 (18.8) 104 (13.8) 0.947
20.6) 201 (27.8) 0.042 50 (17.1) 130 (17.3) 0.939
9.0) 102 (14.1) 0.061 35 (11.9) 108 (14.3) 0.311
32.2) 192 (26.5) 0.115 61 (20.8) 242 (32.1) 0.000
15.6) 126 (17.4) 0.544 46(15.7) 155 (20.6) 0.072
6.0) 47 (6.5) 0.841 25 (8.5) 49 (6.5) 0.251
23.6) 228 (31.5) 0.031 70 (23.9) 254 (33.7) 0.002
21.6) 194 (26.8) 0.138 69 (23.5) 222 (29.5) 0.055
8.0) 65 (9.0) 0.679 29 (9.9) 106 (14.1) 0.07
17.1) 163 (22.5) 0.098 56 (19.1) 164 (21.8) 0.342
34.2) 234 (32.3) 0.622 65 (22.2) 173 (23.0) 0.784
41.7) 331 (45.7) 0.314 85 (29.0) 223 (29.6) 0.847
38.2) 319 (44.1) 0.138 124(42.3) 234 (31.1) 0.001
37.1) 250 (34.5) 0.487 99 (33.8) 232 (30.8) 0.352
24.6) 251 (34.7) 0.007 102 (34.8) 232 (30.8) 0.212
20.1) 156 (21.5) 0.659 57 (19.5) 151 (20.1) 0.827
22.1) 122 (16.9) 0.087 77 (26.3) 160 (21.2) 0.081
13.1) 126 (17.4) 0.144 79 (27.0) 267 (35.5) 0.009
ethods section.
Table 2 Long-term mortality (30day incl.).
CEA AAA LLR
Long-term mortality Female Male p-value Female Male p-value Female Male p-value
154 (27.5) 406 (72.5) 199 (21.6) 724 (78.4) 293 (28) 753 (72)
Cardiac 9 (5.8) 54 (13.3) 0.011 35 (17.6) 127 (17.5) 0.988 66 (22.5) 166 (22) 0.867
Stroke 6 (3.9) 19 (4.7) 0.821 3 (1.5) 32 (4.4) 0.06 8 (2.7) 28 (3.7) 0.571
CCVD 18 (11.7) 79 (19.5) 0.03 46 (23.1) 202 (27.9) 0.177 92 (31.4) 222 (29.5) 0.544
n-CCVD 12 (7.8) 56 (13.8) 0.052 34 (17.1) 129 (17.8) 0.81 42 (14.3) 135 (17.9) 0.164
All-cause mortality 48 (31.2) 176 (43.3) 0.009 101 (50.8) 427 (59) 0.038 166 (56.7) 444 (59) 0.496
For statistical significance of data in bold please refer to Statistical Methods section.
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In Table 1, the patient characteristics of the 923 patients
who underwent intact AAA repair are depicted. Men were
significantly older than women (67 years vs. 63 years;
p Z 0.000) and also more often had COPD, a previous MI,
and more often used aspirin.
There were 528 deaths in total (101 women and 427
men) and higher mortality was seen for men, compared to
women, for overall death and a near significant difference
for death due to stroke (p Z 0.06) (Table 2).
The KM survival curves (Fig. 1b) depict the all-cause
mortality for women and men separately and the log-rank
test (p Z 0.138) demonstrates no statistically significant
difference between men and women.
The disease-specific KM survival curves are lower than the
age- and sex-matched curves of the general population and
the survival advantageamongwomen is lost afterAAA surgery.
The unadjusted HRR for all-cause mortality for men
compared to women was 1.19 (95% CI 0.96e1.48) (not
shown). After adjustment (Table 3), still no statistically
significant differences in all-cause mortality were demon-
strated HRR 0.91 (95% CI 0.73e1.13). Variables that were
independently associated with worse all-cause mortality
were age, COPD and renal dysfunction. Statin use was asso-
ciated with better survival.
The unadjustedHRR for cardiacmortalitywas 1.01 (95%CI
0.70e1.47) (not shown). After adjustment (Table 3), again no
statistically significant differences in cardiac mortality were
demonstrated (HRR 0.75; 95% CI 0.51e1.10). Variables
independently associated with worse cardiac mortality were
age, renal dysfunction, previousMI andprevious intervention.
Lower leg revascularization
In Table 1, the patient characteristics of the 1046 patients
who underwent LLR surgery are depicted. No significant
difference was found in age (66 years vs. 65 years,
pZ 0.07), but men were more often ‘current smokers’, had
a history of an MI and more often used anticoagulation.
Women more often than men had hypertension and more
often used an ACE inhibitor (Table 1).
There were 610 deaths in total (166 women and 444
men) and no differences in mortality were seen for men
compared to women (Table 2).
The KM survival curves (Fig. 1c) depict the all-cause
mortality for women and men separately and the log-ranktest (p Z 0.719) demonstrates no statistically significant
difference between men and women.
The disease-specific KM survival curves are lower than
the age- and sex-matched curves of the general population,
and the survival advantage among women is lost after lower
limb revascularisation.
The unadjusted HRR for all-cause mortality for men was
1.01 (95% CI 0.84e121) (not shown). After adjustment (Table
3), still no statistically significant differences in all-cause
mortality were demonstrated (HRR 1.02; 95% CI 0.85e1.23).
Variables that were independently associated with worse all-
cause mortality were age, diabetes, hypercholesterolemia,
COPD, renal dysfunction, current smoking, heart failure, and
previous MI. Statin use was associated with better survival.
The unadjusted HRR for cardiac mortality was 0.95 (95%
CI 0.71e1.26) (not shown). After adjustment (Table 3),
again no statistically significant differences in cardiac
mortality were demonstrated (HRR 0.85; 95% CI 0.63e1.15).
Variables independently associated with worse cardiac
mortality were age, diabetes, renal dysfunction, angina,
heart failure, previous MI and previous intervention.
Discussion
In the present study, we sought to evaluate whether gender
influenced survival after CEA, AAA repair and LLR. Our data
demonstrated that gender had a statistically significant
impact on long-term all-cause mortality for the CEA group,
with men having an almost 1.5-fold higher mortality
compared to women in multivariable analysis. This worse
long-term all-cause mortality is in accordance with the
worse outcome for men in the general population, as
depicted by the survival curves. For both the AAA group and
the LLR group, gender did not have a statistically significant
influence on long-term all-cause mortality; yet, in
comparison with the survival curves of the general pop-
ulation, women did lose their higher life expectancy.
In the CEA group, there was no age difference between
men and women. Men did have more co-morbidities,
predominantly cardiac related. The fact that there was no
age difference and men had more co-morbidities could
explain the normal course (men having worse survival) of the
survival curves. Men did receive more disease-specific
(aspirin) medication. For the AAA group, however, men were
older, had more co-morbidities, and had higher all-cause
mortality; thus, a normal course of the survival curves is
expected, but now, no difference between the survival curves
Figure 1 (a) Survival curves of women compared with men after CEA, with the age- and sex-matched survival curves of the
general population. (b) Survival curves of women compared with men after AAA repair, with the age- and sex-matched survival
curves of the general population. (c) Survival curves of women compared with men after LLR, with the age- and sex-matched
survival curves of the general population.
514 N. Grootenboer et al.of men and women is seen. Men did receive more disease-
specific (aspirin) medication.
For the LLR group, we see nearly the same situation as
for the AAA group, again, no age difference, co-morbiditieswere equally dispersed, and again, the course of the
survival curve is not normal; the survival curves of men and
women are the same. Here too, men received more
disease-specific medication (anticoagulation).
Table 3 Multivariable adjusted hazard rate ratio (HRR) for long-term all-cause and cardiac mortality for CEA, AAA and LLR.
CEA AAA LLR
All-cause
mortality
Cardiac
mortality
All-cause
mortality
Cardiac
mortality
All-cause
mortality
Cardiac
mortality
Risk factors HRR (95%CI) HRR (95%CI) HRR (95%CI) HRR (95%CI) HRR (95%CI) HRR (95%CI)
Age 1.07
(1.05e1.09)
1.11
(1.07e1.15)
1.05
(1.04e1.06)
1.04
(1.02e1.06)
1.04
(1.03e1.05)
1.04
(1.03e1.05)
Gender 1.41
(1.01e1.98)
2.02
(0.95e4.32)
0.91
(0.73e1.13)
0.75
(0.51e1.10)
1.02
(0.85e1.23)
0.85
(0.63e1.15)
Hypertension 0.95
(0.71e1.28
0.68
(0.37e1.25)
1.06
(0.89e1.28)
0.84
(0.60e1.17)
1.04
(0.87e1.23
1.15
(0.87e1.51)
Diabetes Mellitus 1.84
(1.22e2.77)
1.33
(0.59e2.99)
0.89
(0.68e1.17)
1.45
(0.95e2.23)
1.32
(1.08e1.60)
1.60
(1.19e2.15)
Hypercholesterolemia 2.72
(1.69e4.37)
5.04
(2.28e11.13)
1.25
(0.96e1.64)
1.02
(0.65e1.60)
1.42
(1.07e1.88)
1.96
(0.77e1.85)
COPD 1.01
(0.59e1.72)
0.71
(0.27e1.91)
1.55
(1.28e1.87)
1.16
(0.81e1.66)
1.37
(1.11e1.69)
0.98
(0.69e1.41)
Renal dysfunction 1.88
(1.13e3.12)
1.85
(0.68e4.99)
1.83
(1.44e2.32)
1.82
(1.18e2.79)
1.98
(1.59e2.46)
2.01
(1.42e2.84)
Current smoker 1.21
(0.80e1.83)
0.69
(0.31e1.56)
0.99
(0.81e1.20)
1.01
(0.71e1.42)
1.26
(1.05e1.50)
1.25
(0.94e1.67)
Angina 0.36
(0.20e0.66)
0.10
(0.03e0.32)
1.03
(0.81e1.31)
1.15
(0.78e1.71)
1.15
(0.92e1.42)
1.63
(1.18e2.24)
Heart failure 0.85
(0.30e2.37)
1.16
(0.25e5.45)
1.06
(0.74e1.52)
1.05
(0.60e1.85)
1.42
(1.05e1.90)
1.68
(1.11e2.54)
MI 2.49
(1.50e4.12)
4.42
(1.96e9.98)
1.04
(0.85e1.28)
1.85
(1.31e2.62)
1.25
(1.03e1.53)
1.45
(1.06e1.99)
Previous
Intervention (PCI/CABG)
1.16
(0.80e1.69)
2.67
(1.40e5.10)
1.02
(0.83e1.25)
1.43
(1.01e2.01)
0.93
(0.76e1.14)
1.53
(1.13e2.06)
statin 0.70
(0.47e1.05)
0.80
(0.38e1.67)
0.62
(0.48e0.79)
0.90
(0.60e1.35)
0.68
(0.52e0.90)
0.89
(0.58e1.34)
bbl 1.20
(0.87e1.65)
1.98
(1.11e3.52)
0.93
(0.77e1.12)
0.83
(0.59e1.18)
0.92
(0.76e1.12)
0.83
(0.61e1.13)
asa 0.87
(0.64e1.18)
0.87
(0.47e1.61)
0.90
(0.74e1.11)
0.97
(0.67e1.38)
0.89
(0.74e1.07)
0.93
(0.69e1.25)
For statistical significance of data in bold please refer to Statistical Methods section.
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survival while in the AAA and LLR groups they do not, apart
from differences in medication use, could be explained by
the fact that the CEA groups represent a different category
of patients. Although patients with carotid artery disease
are also thought to have systemic disease,15 AAA and LLR
patients could have a more severe form; also, AAA repair
and LLR pose a greater cardiac stress than CEA.
Our HRRs for long-term mortality comply with previously
published and unpublished univariable and multivariable
HRRs.16,17 Also, women’s retention of their higher life
expectancy after CEA is in line with other studies.18 Medical
undertreatment of surgical patients is a worldwide problem
and was also seen in our data. Both men and women
received too little disease-specific medication, but women
received statistically significantly less medication compared
to men. Often, even though medical treatment is given; the
guideline treatment target is not achieved,15 leading to
insufficient secondary prevention and therefore to higher
recurrence rates and worse survival.
Our study has some limitations. First of all, although our
data were prospectively collected, our hypothesis wasretrospectively established. Secondly, we only investigated
hard outcomes such as mortality and were not able to look
at other outcomes.
Thirdly,weonly had 92% follow-up. In the survival analysis,
a patient who is missing complete follow-up is included in the
analysis as a censored observation. The analysis makes the
assumption that the censoring is non-informative; that is, that
a censored patient has the same risk of death as those who
have complete follow-up. We believe this to be very likely in
our study, as survival status was verified with the municipal
civil registries and that, if missing, that was due to the fact
that patients had moved out of the area; therefore, missing
patients were unlikely to be a selected group of patients.
The present study demonstrated that women lose their
higher life expectancy after AAA repair and LLR.
A possible explanation is the difference in medical
treatment. Both men and women received too little
disease-specific medication in all three surgical groups, but
women were worse off. Further research should focus on
explanations other than medication too, such as gender
differences in (non-fatal) events in the intra-operative
period and their relation to survival.
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